Family History of Gastric Cancer and Helicobacter pylori Treatment

To the Editor: In the trial reported by Choi et al. (Jan. 30 issue), 1 participants with Helicobacter pylori infection were assigned to receive eradication treatment or placebo. Patients in the treatment group received clarithromycin-containing triple therapy twice a day for 7 days. At the end of th...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:The New England journal of medicine 2020-05, Vol.382 (22), p.2170-2172
Hauptverfasser: Salman, Genene, Vo, Kim, Rodriguez, Gladys M, Hernandez, Marisol C, Lin, Albert Y, Yuan, Guandou, Chen, Yubing, He, Songqing, Kim, Young-Il, Park, Boram, Choi, Il Ju
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:To the Editor: In the trial reported by Choi et al. (Jan. 30 issue), 1 participants with Helicobacter pylori infection were assigned to receive eradication treatment or placebo. Patients in the treatment group received clarithromycin-containing triple therapy twice a day for 7 days. At the end of the trial, patients in either group who were still infected with H. pylori were treated with bismuth-based quadruple therapy for 10 days. 1 It is important to note that the American College of Gastroenterology guidelines for H. pylori treatment underwent updates during the time the trial was being conducted. 2-4 Clarithromycin-based triple therapy is no longer . . .
ISSN:0028-4793
1533-4406
DOI:10.1056/NEJMc2003542